Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.60), $0.69 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $38.02 million versus the consensus estimate of $140.61 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.